Lab
Rapid Lab
Rapid Lab was paid $269K by Medicaid between Feb 2024 and Dec 2024, across 46 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 25% of everything it billed.
33Billing provider infoRAPID LAB
NORTH LAS VEGAS, NV 89030
NORTH LAS VEGAS, NV 89030
33aNPI1871181081assigned 01/04/2021
33bProvider typeClinical Medical Laboratory
28Total paid$269K
24GClaims11,963
24DCodes billed46
24AFirst – last monthFeb 2024 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Nevada
Rank by total paid#16 of 31
Median peer was paid$269K
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2024incomplete | 11,963 | $269K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 25% | 3,806 | 3,485 | $69K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 25% | 2,651 | 2,413 | $68K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 11% | 553 | 120 | $31K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 8.5% | 241 | 182 | $23K |
| 87634 | 8.5% | 553 | 120 | $23K | |
| 87150 | 6.7% | 199 | 169 | $18K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.0% | 553 | 120 | $13K |
| 87481 | 1.4% | 219 | 174 | $4K | |
| 87500 | <1% | 187 | 157 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 126 | 123 | $2K |
| 87653 | <1% | 224 | 178 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 122 | 104 | $2K |
34 more codes
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 122 | $2K |
| 87640 | <1% | 150 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 143 | $1K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 122 | $1K |
| 80050 | General health panel | <1% | 66 | $1K |
| 87563 | <1% | 116 | $1K | |
| 80061 | Lipid panel | <1% | 247 | $959.70 |
| 87510 | <1% | 123 | $684.00 | |
| 82607 | <1% | 134 | $544.84 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 162 | $463.40 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 162 | $435.86 |
| 84153 | <1% | 58 | $401.60 | |
| 80053 | Comprehensive metabolic panel | <1% | 186 | $310.03 |
| 87109 | <1% | 20 | $252.00 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 184 | $223.02 |
| 83880 | <1% | 16 | $208.44 | |
| 84403 | <1% | 18 | $193.71 | |
| 86696 | <1% | 20 | $158.40 | |
| 82378 | <1% | 46 | $155.28 | |
| 84550 | <1% | 102 | $141.68 | |
| 83090 | <1% | 20 | $126.61 | |
| 86800 | <1% | 21 | $119.35 | |
| 84480 | <1% | 24 | $116.04 | |
| 86695 | <1% | 20 | $108.00 | |
| 86376 | <1% | 20 | $99.30 | |
| 83735 | <1% | 32 | $86.83 | |
| 84439 | <1% | 25 | $73.80 | |
| 83690 | <1% | 20 | $51.70 | |
| 82150 | <1% | 20 | $48.62 | |
| 83550 | <1% | 17 | $47.80 | |
| 86140 | <1% | 19 | $35.30 | |
| 81003 | <1% | 59 | $19.89 | |
| 85652 | <1% | 19 | $18.50 | |
| 81001 | <1% | 16 | $4.32 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPHARMER, TIFFANY (LAB OWNER)